FDA Approves Inlyta (axitinib) for Advanced Renal Cell Carcinoma

Share this content:

(ChemotherapyAdvisor) – The U.S. Food and Drug Administration (FDA) has approved the oral kinase inhibitor Inlyta (axitinib) for the treatment of patients with advanced renal cell carcinoma (RCC).

Approval was based on results of the open-label, multicenter, phase 3 AXIS trial, in which 723 patients with advanced RCC who had failed one prior systemic therapy were randomized to second-line axitinib 5mg orally twice daily or sorafenib 400mg orally twice daily.

The primary efficacy end point was progression-free survival (PFS), as assessed by an Independent Review Committee consisting of two blinded radiologists. Median PFS was 6.7 months (95% CI 6.3–8.4) for axitinib and 4.7 months (95% CI 4.6–5.6) for sorafenib; the hazard ratio was 0.67 (95% CI 0.55–0.81).

The adverse events (AEs) observed with axitinib were comparable to agents in the same class of small molecule inhibitors of the VEGF pathway: diarrhea, nausea, fatigue, asthenia, hypertension, and hand-foot syndrome (palmar-plantar erythrodysesthesia), weight loss, vomiting, and constipation. Patients with hypertension should have it well-controlled before taking axitinib, the FDA noted.

Less common AEs included arterial and venous thrombotic events, gastrointestinal perforation, bleeding events, hypothyroidism, dysphonia, proteinuria, and reversible posterior leukoencephalopathy syndrome.

According to the FDA, axitinib is the seventh drug approved for the treatment of metastatic or advanced RCC since 2005. Others are sorafenib (2005), sunitinib (2006), temsirolimus (2007), everolimus (2009), bevacizumab (2009) and pazopanib (2009).

Axitinib is marketed by Pfizer, Inc.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs